Surgery and Sentinel Lymph Node Biopsy

Seminars in Oncology

Volumn 34, Issue 6, 2007, Pages 498-508

  Faries, Mark B ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MINIMALLY INVASIVE SURGERY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SURGICAL DRAINAGE;

HUMANS; LYMPH NODE EXCISION; MELANOMA; PATIENT SELECTION; RESEARCH; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 36849081266     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.09.010     Document Type: Article

References (112)

1. McLeod G., Davis N., and Sober A. A history of melanoma from Hunter to Clark. In: Balch C., Houghton A., Sober A., et al. (Eds). Cutaneous Melanoma. (ed 4) (2003), Quality Medical Publishing, St. Louis, MO 1-11
2. Olsen G. The malignant melanoma of the skin. New theories based on a study of 500 cases. Acta Chir Scand Suppl 365 (1966) 1-222
3. Wong C.K. A study of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica 141 (1970) 215-225
4. Cochran A.J. Studies of the melanocytes of the epidermis adjacent to tumors. J Invest Dermatol 57 (1971) 38-43
5. Veronesi U., and Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 126 (1991) 438-441
6. Balch C.M., Soong S.J., Smith T., et al. Long-term results of a prospective surgical trial comparing 2 cm v 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 8 (2001) 101-108
7. Thomas J.M., Newton-Bishop J., A'Hern R., et al. Excision margins in high-risk malignant melanoma. N Engl J Med 350 (2004) 757-766
8. Cohn-Cedermark G., Rutqvist L.E., Andersson R., et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 89 (2000) 1495-1501
9. Khayat D., Rixe O., Martin G., et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 97 (2003) 1941-1946
10. Balch C.M., Urist M.M., Karakousis C.P., et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 218 (1993) 262-267
11. Ringborg U., Brahme E.M., and Drewiecki K. Ranomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm (2005), World Congress on Melanoma, Vancouver, BC, Canada September 6-10
12. Haigh P.I., DiFronzo L.A., and McCready D.R. Optimal excision margins for primary cutaneous melanoma: A systematic review and meta-analysis. Can J Surg 46 (2003) 419-426
13. Posther K.E., Selim M.A., Mosca P.J., et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol 13 (2006) 728-739
14. Balch C., Soong S., Ross M., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Ann Surg Oncol 7 (2000) 87-97
15. Thompson J.F., Scolyer R.A., and Uren R.F. Surgical management of primary cutaneous melanoma: Excision margins and the role of sentinel lymph node examination. Surg Oncol Clin N Am 15 (2006) 301-318
16. Gould E.A., Winship T., Philbin P.H., et al. Observations on a "sentinel node" in cancer of the parotid. Cancer 13 (1960) 77-78
17. Cabanas R. An approach for the treatment of penile carcinoma. Cancer 39 (1977) 456-466
18. Holmes E., Moseley H., Morton D., et al. A rational approach to the surgical management of melanoma. Ann Surg 186 (1977) 481-490
19. Fee H.J., Robinson D.S., Sample W.F., et al. The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: A preliminary study. Surgery 84 (1978) 626-632
20. Wong J., Cagle L., and Morton D. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 214 (1991) 637-641
21. Morton D., Cagle L., and Wong J. Intraoperative lymphatic mapping and selective lymphadenectomy: Technical details of a new procedure for clinical stage I melanoma (1990) Presented at the 42nd Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 20-22
22. Morton D., Wen D., Wong J., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 (1992) 392-399
23. Alex J.C., and Krag D.N. Gamma-probe guided localization of lymph nodes. Surg Oncol 2 (1993) 137-143
24. Essner R., Foshag L., and Morton D. Intraoperative radiolymphoscintigraphy: A useful adjunct to intraoperative lymphatic mapping and selective lymphadenectomy in patients with clinical stage I melanoma (1994), Society of Surgical Oncology Annual Meeting, Houston, TX March 17-20
25. Glass E.C., Essner R., and Morton D.L. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med 39 (1998) 1185-1190
26. Uren R.F., Thompson J.F., Howman-Giles R., et al. The role of lymphoscintigraphy in the detection of lymph node drainage in melanoma. Surg Oncol Clin N Am 15 (2006) 285-300
27. Morton D.L., Thompson J.F., Essner R., et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230 (1999) 453-463
28. Wong S.L., Kattan M.W., McMasters K.M., et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol 12 (2005) 282-288
29. Rousseau DL Jr, Ross MI, Johnson MM, et al: Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10:569-574, 203
30. Morton D., Hoon D., Cochran A., et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: Therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 238 (2003) 538-549
31. Gershenwald J.E., Mansfield P.F., Lee J.E., et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 7 (2000) 160-165
32. Ranieri J.M., Wagner J.D., Wenck S., et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 13 (2006) 927-932
33. Agnese D.M., Abdessalam S.F., Burak Jr. W.E., et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 134 (2003) 542-547
34. Bleicher R.J., Essner R., Foshag L.J., et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 21 (2003) 1326-1331
35. Bedrosian I., Faries M.B., Guerry D.T., et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 7 (2000) 262-267
36. Stitzenberg K.B., Groben P.A., Stern S.L., et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol 11 (2004) 900-906
37. Hershko D.D., Robb B.W., Lowy A.M., et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol 93 (2006) 279-285
38. Olah J., Gyulai R., Korom I., et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 149 (2003) 662-663
39. Wong S.L., Brady M.S., Busam K.J., et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 13 (2006) 302-309
40. Vaquerano J., Kraybill W.G., Driscoll D.L., et al. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 13 (2006) 198-204
41. Puleo C.A., Messina J.L., Riker A.I., et al. Sentinel node biopsy for thin melanomas: Which patients should be considered?. Cancer Control 12 (2005) 230-235
42. Koskivuo I., Suominen E., Niinikoski J., et al. Sentinel node metastasectomy in thin
43. Kesmodel S.B., Karakousis G.C., Botbyl J.D., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12 (2005) 449-458
44. Jacobs I.A., Chang C.K., DasGupta T.K., et al. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol 10 (2003) 558-561
45. Lowe J.B., Hurst E., Moley J.F., et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 139 (2003) 617-621
46. Oliveira Filho R.S., Ferreira L.M., Biasi L.J., et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 36 (2003) 347-350
47. Woods J.E., Soule E.H., and Creagan E.T. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg 198 (1983) 63-64
48. Corsetti R.L., Allen H.M., and Wanebo H.J. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 7 (2000) 456-460
49. Karakousis G.C., Gimotty P.A., Botbyl J.D., et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 13 (2006) 533-541
50. Kalady M.F., White R.R., Johnson J.L., et al. Thin melanomas: Predictive lethal characteristics from a 30-year clinical experience. Ann Surg 238 (2003) 528-535
51. Nahabedian M.Y., Tufaro A.P., and Manson P.N. Sentinel lymph node biopsy for the T1 (thin) melanoma: Is it necessary?. Ann Plast Surg 50 (2003) 601-606
52. Massi D., Franchi A., Borgognoni L., et al. Thin cutaneous malignant melanomas (< or =1.5 mm): Identification of risk factors indicative of progression. Cancer 85 (1999) 1067-1076
53. Schmid-Wendtner M.H., Baumert J., Eberle J., et al. Disease progression in patients with thin cutaneous melanomas (tumour thickness < or = 0.75 mm): Clinical and epidemiological data from the Tumour Center Munich 1977-98. Br J Dermatol 149 (2003) 788-793
54. McKinnon J.G., Yu X.Q., McCarthy W.H., et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 98 (2003) 1223-1231
55. Naruns P.L., Nizze J.A., Cochran A.J., et al. Recurrence potential of thin primary melanomas. Cancer 57 (1986) 545-548
56. Balch C., Buzaid A., Soong S., et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 19 (2001) 3635-3648
57. Faries MB, Essner R, Foshag L, et al: Lymph flow decreases with age and correlates with non-sentinel node metastasis and poor survival in stage III melanoma. Proc Am Assoc Cancer Res 47:2006 (abstr 4766)
58. Su L.D., Fullen D.R., Lowe L., et al. Desmoplastic and neurotropic melanoma. Cancer 100 (2004) 598-604
59. Gyorki D.E., Busam K., Panageas K., et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol 10 (2003) 403-407
60. Pawlik T.M., Ross M.I., Prieto V.G., et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 106 (2006) 900-906
61. Hawkins W.G., Busam K.J., Ben-Porat L., et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 12 (2005) 207-213
62. Thompson J.F., and Uren R.F. Teaching points on lymphatic mapping for melanoma from the Sydney Melanoma Unit. Semin Oncol 31 (2004) 349-356
63. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 24 suppl 4 (1997) S8-S10
64. McMasters K.M., Chao C., Wong S.L., et al. Interval sentinel lymph nodes in melanoma. Arch Surg 137 (2002) 543-547
65. Stradling B., Aranha G., and Gabram S. Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg 184 (2002) 350-352
66. McMasters K., Reintgen D., Ross M., et al. Sentinel lymph node biopsy for melanoma: How many radioactive nodes should be removed?. Ann Surg Oncol 8 (2001) 192-197
67. Forbes R.C., Pitchford C., Simpson J.F., et al. Selective use of intraoperative touch prep analysis of sentinel nodes in breast cancer. Am Surg 71 (2005) 955-960
68. Kane III J.M., Edge S.B., Winston J.S., et al. Intraoperative pathologic evaluation of a breast cancer sentinel lymph node biopsy as a determinant for synchronous axillary lymph node dissection. Ann Surg Oncol 8 (2001) 361-367
69. Rubio I.T., Korourian S., Cowan C., et al. Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. Ann Surg Oncol 5 (1998) 689-694
70. Creager A.J., Shiver S.A., Shen P., et al. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Cancer 94 (2002) 3016-3022
71. Shidham V.B., Chang C.C., and Komorowski R. MCW melanoma cocktail for the evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma. Expert Rev Mol Diagn 5 (2005) 281-290
72. Morton D., Cochran A., Thompson J., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg 242 (2005) 302-311
73. Wrightson W.R., Wong S.L., Edwards M.J., et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 10 (2003) 676-680
74. Estourgie S.H., Nieweg O.E., and Kroon B.B. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 91 (2004) 1370-1371
75. Thomas J.M., and Clark M.A. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 30 (2004) 686-691
76. Pawlik T.M., Ross M.I., Thompson J.F., et al. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23 (2005) 4588-4590
77. van Poll D., Thompson J.F., Colman M.H., et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 12 (2005) 597-608
78. Kang J.C., Wanek L.A., Essner R., et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 23 (2005) 4764-4770
79. Essner R., Conforti A., Kelley M.C., et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 6 (1999) 442-449
80. Gershenwald J.E., Colome M.I., Lee J.E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16 (1998) 2253-2260
81. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 (2006) 1307-1317
82. Lee J.H., Essner R., Torisu-Itakura H., et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22 (2004) 3677-3684
83. Sabel M.S., Griffith K., Sondak V.K., et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 201 (2005) 37-47
84. Reeves M.E., Delgado R., Busam K.J., et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10 (2003) 27-31
85. Wagner J.D., Davidson D., Coleman III J.J., et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol 6 (1999) 398-404
86. Cochran A.J., Wen D.R., Huang R.R., et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17 (2004) 747-755
87. Wallace A.M., Hoh C.K., Vera D.R., et al. Lymphoseek: A molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol 10 (2003) 531-538
88. Scoggins C.R., Ross M.I., Reintgen D.S., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24 (2006) 2849-2857
89. Takeuchi H., Morton D.L., Kuo C., et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22 (2004) 2671-2680
90. Cochran A.J., Huang R.R., Lee J., et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6 (2006) 659-670
91. Gajewski T.F., Meng Y., and Harlin H. Immune suppression in the tumor microenvironment. J Immunother 29 (2006) 233-240
92. Eisengart C.A., Mestre J.R., Naama H.A., et al. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol 204 (2000) 143-149
93. Lee J.H., Torisu-Itakara H., Cochran A.J., et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11 (2005) 107-112
94. Wen D.R., Hoon D.S., Chang C., et al. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 30 (1989) 277-282
95. Cochran A.J., Wen D.R., Farzad Z., et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res 9 (1989) 859-864
96. Miyasaka M., and Tanaka T. Lymphocyte trafficking across high endothelial venules: Dogmas and enigmas. Nat Rev Immunol 4 (2004) 360-370
97. Cochran A.J., Morton D.L., Stern S., et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment. Mod Pathol 14 (2001) 604-608
98. Morton D., Ollila D., Hsueh E., et al. Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma. CA Cancer J Clin 49 (1999) 101-116
99. Ollila D.W. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 7 (2006) 919-924
100. Allen P.J., and Coit D.G. The surgical management of metastatic melanoma. Ann Surg Oncol 9 (2002) 762-770
101. Ollila D., and Morton D. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am 8 (1998) 183-196
102. Faries M.B., Bleicher R.J., Ye X., et al. Lymphatic mapping and sentinel lymphadenectomy for primary and metastatic pulmonary malignant neoplasms. Arch Surg 139 (2004) 870-876
103. Pawlik T., Zorzi D., Abdalla E., et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13 (2006) 712-720
104. Wood T., DiFronzo A., Rose M., et al. Does complete resection of melanoma metastatic to solid intraabdominal organs improve survival?. Ann Surg Oncol 8 (2001) 658-662
105. Ollila D., Essner R., Wanek L., et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131 (1996) 975-979
106. Morton D., Mozzillo N., Thompson J., et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 13 suppl (2006) 5s
107. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
108. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20 (2002) 2045-2052
109. Giuliano A., Kirgan D., Guenther J., et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220 (1994) 391-398
110. Liptay M., Grondin S., Fry W., et al. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol 20 (2002) 1984-1988
111. Bilchik A., Nora D., Tollenaar R., et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer 38 (2002) 977-985
112. Bilchik A.J., Giuliano A., Essner R., et al. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 4 (1998) 351-358